CORT
Corcept Therapeutics Incorporated
Stock
$116.23+2.20 (+1.93%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $831M | $761M | $675M | $482M | $402M | $366M | $354M | $306M | $251M | $159M | $81M | $29K |
| Cost of revenue | $14M | $13M | $11M | $6.5M | $5.4M | $5.3M | $5.6M | $5.5M | $5.2M | $3.6M | $2.1M | — |
| Gross profit | $817M | $748M | $664M | $476M | $396M | $361M | $348M | $301M | $246M | $156M | $79M | — |
| R&D | $254M | $255M | $247M | $184M | $131M | $114M | $115M | $89M | $75M | $40M | $24M | $14M |
| SG&A | $556M | $449M | $280M | $184M | $153M | $122M | $105M | $100M | $81M | $62M | $45M | — |
| Operating income | $6.4M | $45M | $137M | $107M | $113M | $124M | $128M | $112M | $89M | $53M | $10M | −$20M |
| Non-operating income | $20M | $22M | $25M | $17M | $3.6M | $529K | $3.4M | $5.1M | $2.7M | −$49K | −$2.0M | — |
| Pretax income | $26M | $66M | $161M | $125M | $116M | $125M | $132M | $117M | $92M | $53M | $8.1M | — |
| Taxes | −$29M | −$33M | $20M | $18M | $15M | $12M | $26M | $22M | $17M | −$76M | $0 | — |
| Net income | $55M | $100M | $141M | $106M | $101M | $113M | $106M | $94M | $75M | $129M | $8.1M | −$20M |
| Diluted EPS | $0.42 | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 | $0.85 | $0.77 | $0.60 | $1.04 | $0.07 | −$0.38 |
| Diluted shares | — | 120.0M | 113.5M | 111.7M | 116.0M | 126.0M | 124.2M | 122.6M | 126.7M | 124.5M | 116.1M | — |
| Revenue growth | — | +12.8% | +39.9% | +20.0% | +9.8% | +3.4% | +15.5% | +22.0% | +57.8% | +95.8% | — | — |
| Gross margin | 98.3% | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | 98.4% | 98.2% | 97.9% | 97.8% | 97.5% | — |
| Operating margin | 0.8% | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | 36.2% | 36.4% | 35.6% | 33.2% | 12.5% | −69,827.6% |
| Net margin | 6.6% | 13.1% | 20.9% | 22.0% | 25.2% | 30.7% | 30.0% | 30.7% | 30.0% | 81.1% | 10.0% | −69,537.9% |